The primary benefit of Dengvaxia is its ability to reduce the incidence of dengue in vaccinated populations, potentially leading to fewer hospitalizations and lower healthcare costs. However, there are risks associated with the vaccine, especially in seronegative individuals (those who have never had dengue). In such cases, the vaccine may increase the risk of severe dengue upon subsequent infection.
